Insulet (PODD) Competitors $330.84 -2.67 (-0.80%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$330.96 +0.12 (+0.04%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PODD vs. BDX, IDXX, EW, RMD, DXCM, STE, HOLX, BAX, GMED, and MASIShould you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), ResMed (RMD), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Baxter International (BAX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry. Insulet vs. Its Competitors Becton, Dickinson and Company IDEXX Laboratories Edwards Lifesciences ResMed DexCom STERIS Hologic Baxter International Globus Medical Masimo Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations. Which has more volatility and risk, BDX or PODD? Becton, Dickinson and Company has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Which has higher valuation and earnings, BDX or PODD? Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBecton, Dickinson and Company$21.39B2.51$1.71B$5.5633.68Insulet$2.07B11.24$418.30M$3.29100.56 Is BDX or PODD more profitable? Insulet has a net margin of 10.01% compared to Becton, Dickinson and Company's net margin of 7.51%. Insulet's return on equity of 23.78% beat Becton, Dickinson and Company's return on equity.Company Net Margins Return on Equity Return on Assets Becton, Dickinson and Company7.51% 16.23% 7.46% Insulet 10.01%23.78%9.30% Does the media prefer BDX or PODD? In the previous week, Becton, Dickinson and Company had 9 more articles in the media than Insulet. MarketBeat recorded 41 mentions for Becton, Dickinson and Company and 32 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.45 beat Insulet's score of 1.01 indicating that Becton, Dickinson and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 35 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 17 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in BDX or PODD? 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate BDX or PODD? Becton, Dickinson and Company currently has a consensus target price of $213.30, suggesting a potential upside of 13.90%. Insulet has a consensus target price of $343.06, suggesting a potential upside of 3.69%. Given Becton, Dickinson and Company's higher probable upside, analysts plainly believe Becton, Dickinson and Company is more favorable than Insulet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Becton, Dickinson and Company 0 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.36Insulet 0 Sell rating(s) 2 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.89 SummaryInsulet beats Becton, Dickinson and Company on 9 of the 16 factors compared between the two stocks. Get Insulet News Delivered to You Automatically Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PODD vs. The Competition Export to ExcelMetricInsuletMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.29B$10.61B$5.81B$10.44BDividend YieldN/A1.88%5.61%4.56%P/E Ratio100.5621.6480.5026.82Price / Sales11.2440.59452.1890.24Price / Cash74.5724.5137.6661.43Price / Book19.163.4215.756.39Net Income$418.30M$210.63M$3.30B$271.80M7 Day Performance-3.20%-0.02%5.35%3.51%1 Month Performance0.91%0.69%7.28%9.58%1 Year Performance39.84%-9.87%80.79%28.53% Insulet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PODDInsulet4.5807 of 5 stars$330.84-0.8%$343.06+3.7%+39.8%$23.29B$2.07B100.563,900News CoveragePositive NewsAnalyst ForecastBDXBecton, Dickinson and Company4.9595 of 5 stars$191.50-0.5%$211.44+10.4%-19.8%$55.14B$21.39B34.4474,000News CoveragePositive NewsIDXXIDEXX Laboratories4.1454 of 5 stars$652.83+1.5%$649.44-0.5%+29.5%$51.44B$4.04B54.3611,000Positive NewsAnalyst UpgradeEWEdwards Lifesciences4.7991 of 5 stars$80.28-0.8%$85.90+7.0%+11.3%$47.52B$5.44B11.5515,800Positive NewsAnalyst UpgradeShort Interest ↑RMDResMed4.7564 of 5 stars$279.38+0.8%$278.36-0.4%+11.7%$40.56B$5.15B29.3810,600Positive NewsAnalyst UpgradeDXCMDexCom4.9772 of 5 stars$78.00-3.1%$99.89+28.1%-4.2%$31.57B$4.03B54.1710,300Trending NewsOptions VolumeSTESTERIS4.8844 of 5 stars$248.41+1.3%$273.50+10.1%+4.9%$24.16B$5.46B38.0417,787Trending NewsAnalyst RevisionHigh Trading VolumeHOLXHologic4.8315 of 5 stars$66.54-0.3%$78.00+17.2%-18.5%$14.85B$4.03B27.617,063Trending NewsAnalyst ForecastAnalyst RevisionBAXBaxter International4.8366 of 5 stars$24.08-1.4%$30.11+25.1%-40.2%$12.54B$10.64B-80.2538,000GMEDGlobus Medical4.8064 of 5 stars$59.37-2.0%$87.64+47.6%-20.8%$8.18B$2.52B22.835,300Positive NewsInsider TradeMASIMasimo4.5968 of 5 stars$148.79+1.1%$193.60+30.1%+15.7%$8.00B$2.15B-17.465,600Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Becton, Dickinson and Company Alternatives IDEXX Laboratories Alternatives Edwards Lifesciences Alternatives ResMed Alternatives DexCom Alternatives STERIS Alternatives Hologic Alternatives Baxter International Alternatives Globus Medical Alternatives Masimo Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PODD) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
